Rivastigmine

• Nootropic Agents
• Cholinergic Agents
• Parasympathomimetics
• ATC:N06DA03

• Ena 713 Free Base
• Exelon
• Rivastigmine Hydrogen Tartrate
• Rivastigmine [Usan:Inn]

• No information avaliable

C₁₄H₂₂N₂O₂

http://www.rxlist.com/cgi/generic2/rivastig.htm

Rivastigmine FDA

No information avaliable

250.337 g/mol

No information avaliable

No information avaliable

Solid

2.611

Capsule; Solution

For the treatment of mild to moderate Alzheimer's disease.

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.

No information avaliable

No information avaliable

Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.

Humans and other mammals